Brought to you by 
Almirall licenses COPD agent to Forest
29 Oct 2020
Executive Summary
Spanish pharma Almirall (treatments for respiratory and autoimmune diseases) licensed Forest Laboratories US sales and marketing rights to its Phase III candidate LAS34273 for chronic obstructive pulmonary disease (COPD).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Pulmonary
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Almirall licenses COPD agent to Forest
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice